Skip to main content

Loblaw Companies Limited Announces the Timing of the First Quarter 2026 Earnings Release and Annual Meeting of Shareholders

BRAMPTON, Ontario, April 08, 2026 (GLOBE NEWSWIRE) — Loblaw Companies Limited (TSX: L) announced today that it will release its 2026 first quarter results on May 6th, 2026, at approximately 6:30 a.m. (ET). The release will be followed by a conference call at 10:00 a.m. (ET), as well as an audio webcast. To access via audio webcast please go to the “Investor” section of loblaw.ca and note that pre-registration will be available. Alternatively, please dial (647) 932-3411 or Toll-Free (800) 715-9871. Following the live event, the webcast will be archived and available to replay for 12 months. This year the Loblaw Companies Limited Annual Meeting of Shareholders will be held on May 12, 2026, at 10:00 a.m. (ET), at Massey Hall, 178 Victoria Street, Toronto, Ontario, Canada. Shareholders who are not able to attend in person will be able...

Continue reading

Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Enabling Phase 3 DAYBreak CLL-306 bexobrutideg confirmatory trial for full approval in r/r CLL Targeting 2026 IND submission for bexobrutideg in inflammatory and autoimmune indications with a new tablet formulation Continuing advancement of targeted protein degraders of IRAK4 in Phase 1 and STAT6 in IND-enabling studies under strategic partnerships Well capitalized with $540.7 million on the balance sheet BRISBANE, Calif., April 08, 2026 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today reported financial results for...

Continue reading

Stella-Jones’ First Quarter 2026 Results Conference Call and Annual Meeting of Shareholders

MONTRÉAL, April 08, 2026 (GLOBE NEWSWIRE) — Stella-Jones Inc. (TSX: SJ), (“Stella-Jones” or the “Company”) will hold a conference call to discuss its first quarter results:  Open to: Investors, analysts and all interested parties  Date: Wednesday, May 6, 2026  Time: 8:00 AM Eastern Daylight Time (EDT)  Live Webcast: https://meetings.lumiconnect.com/400-925-467-567  Call: Local – Toronto: +1 (416) 855-9085 Toll Free – North America: +1 (800) 990-2777 Conference ID: 85640     The press release will be published before market opens the day of the conference call through Globe Newswire. Please log on or dial in 15 minutes before the conference begins. If you are unable to attend at this time, you may access a web recording of the meeting at the following link: https://meetings.lumiconnect.com/400-925-467-567....

Continue reading

Lerøy Seafood Group ASA: Trading update Q1 2026

HARVEST VOLUMES OF SALMON AND TROUT Total harvest volume of salmon and trout for Q1 2026 was 39,900 GWT, compared to 38,200 GWT in Q1 2025. These figures exclude harvest volumes from Scottish Seafarms. Harvest volumes by region for Q1 2026 (Q1 2025), measured in 1,000 GWT:Lerøy Aurora: 8.3 (7.1) Lerøy Midt: 16.0 (16.4) Lerøy Sjøtroll: 15.7 of which 6.1 were trout (14.8 of which 9.5 were trout)CATCH VOLUMES OF WILDFISH Total wild catch volumes in Lerøy Havfisk, measured in 1,000 tonnes:Q1 2026: 14.3 of which 2.7 were cod Q1 2025: 19.0 of which 3.6 were codThe complete Q1 2026 report will be released on 12 May at 06:30 CET. Queries may be addressed to the company’s CFO, Sjur S. Malm. This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

Continue reading

Firm Capital Apartment REIT Provides Strategic Review Update, Q4/2025 and 2025 Results

All figures in $USD unless otherwise noted. TORONTO, April 07, 2026 (GLOBE NEWSWIRE) — Firm Capital Apartment Real Estate Investment Trust (“the “Trust”), (TSXV: FCA.U), (TSXV: FCA.UN) is pleased to report its financial results for the three and twelve months ended December 31, 2025 and provide a Strategic Review update: EARNINGS Excluding non-cash fair value adjustments, net income for the three months ended December 31, 2025 was approximately $0.1 million, in line with the $0.1 million net income reported for the three months ended September 30, 2025, and the $0.1 million net income reported for the three months ended December 31, 2024. Excluding non-cash fair value adjustments, for the twelve months ended December 31, 2025, net income was approximately $0.7 million, in comparison to the $0.15 million net loss reported for the...

Continue reading

Xcel Brands, Inc. Announces Fourth Quarter Year-End 2025 Financial Results

Net loss on a GAAP basis was $2.8 million for the current quarter compared with a net loss of $7.1 million for the prior year quarter, each period inclusive of various non-cash charges, representing a $4.3 million improvement year-over-year. Net loss on a non-GAAP basis was $1.6 million for the current and prior year quarters. Current quarter Adjusted EBITDA was negative $0.61 million, compared with Adjusted EBITDA of negative $0.79 million for the prior year quarter, representing a 24% improvement. Full year Adjusted EBITDA for 2025 was negative $2.3 million, compared with Adjusted EBITDA of negative $3.5 million for the prior year, representing a 35% improvement.NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) — Xcel Brands, Inc. (NASDAQ: XELB) (“Xcel” or the “Company”), a media and consumer products company with significant expertise...

Continue reading

NovaBridge Reports Full Year 2025 Financial Results and Provides Business Update

Successful transformation to global biotech platform with two mid-stage potential best-in-class/first-in-class programs, givastomig and VIS-101, with compelling proof-of-concept data Givastomig, a potential best-in-class/first-in-class Claudin 18.2-directed bispecific antibody for gastric cancer, has shown robust and durable responses with broad CLDN18.2 activity, favorable safety, as well as potential eligibility for FDA’s Accelerated Approval Pathway with potential initiation of a registrational Phase 3 trial as early as Q4 2026 VIS-101, a potential best-in-class VEGF-A X ANG-2 inhibitor for wet-AMD, produced rapid, robust and durable responses in treatment naïve wet-AMD patients, and is poised to begin Phase 2b studies in H2 2026 Expanded, world-class Board of Directors and Executive Team in place to drive growth Strong financial position...

Continue reading

Kura Sushi USA Announces Fiscal Second Quarter 2026 Financial Results

IRVINE, Calif., April 07, 2026 (GLOBE NEWSWIRE) — Kura Sushi USA, Inc. (“Kura Sushi” or the “Company”) (NASDAQ: KRUS), a technology-enabled Japanese restaurant concept, today announced financial results for the fiscal second quarter ended February 28, 2026. Fiscal Second Quarter 2026 HighlightsTotal sales were $80.0 million, compared to $64.9 million in the second quarter of 2025; Comparable restaurant sales increased 8.6% for the second quarter of 2026 as compared to the second quarter of 2025; Operating loss was $2.2 million, compared to an operating loss of $4.6 million in the second quarter of 2025; Net loss was $1.7 million, or $(0.14) per diluted share, compared to net loss of $3.8 million, or $(0.31) per diluted share, in the second quarter of 2025; Adjusted net loss* was $0.5 million, or $(0.04) per diluted share, compared...

Continue reading

XPO Schedules First Quarter 2026 Earnings Conference Call for Thursday, April 30, 2026

GREENWICH, Conn., April 07, 2026 (GLOBE NEWSWIRE) — XPO (NYSE: XPO) will hold its first quarter conference call and webcast on Thursday, April 30, at 8:30 a.m. Eastern Time. The company’s results will be released earlier that morning and made available on www.xpo.com. Access information:Call toll-free from US/Canada: 1-877-269-7756International callers: +1-201-689-7817Live webcast online at: www.xpo.com/investors A replay of the conference call will be available until May 30, 2026, by calling toll-free (from US/Canada) 1-877-660-6853; international callers dial +1-201-612-7415. Use the passcode 13759585. Additionally, the call will be archived on www.xpo.com/investors.About XPOXPO, Inc. (NYSE: XPO) is a leader in asset-based less-than-truckload (LTL) freight transportation in North America. The company’s customer-focused organization...

Continue reading

EPH European Property Holdings PLC Profit / Loss Warning – EPH expects net profit in its consolidated accounts for the YE 2025 compared to the previous year

07 April 2026, Limassol, Cyprus / Ad hoc announcement pursuant to Art. 53 LR EPH European Property Holdings PLC (“EPH”, the “Company”) would like to announce that the Company expects a net profit of approximately EUR 14-16 million for the year 2025, compared to a net loss of EUR 3.03 million in the previous year. The trends of the first half-year 2025 continued to the year-end 2025. The main factor behind the positive change in financial results is a gain on revaluation of investment properties of approximately EUR 9 million, recognized in the reporting period, resulting primarily from a slight increase in market rental rates and stabilization of discount and capitalization rates at the level of YE 2024. In 2024, EPH recognised a loss of EUR 24 million on revaluation of investment properties as a result of rising capitalization and discount...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.